Nuvectis Pharma (NVCT) EBT (2021 - 2026)

Nuvectis Pharma has disclosed EBT across 6 years of filings, most recently posting -$6.0 million for Q1 2026.

• EBT for Q1 2026 came in at -$6.0 million, down 13.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$27.2 million (down 34.72% YoY), and the FY2025 annual result was -$26.4 million, down 39.17% from the prior year.
• EBT came in at -$6.0 million for Q1 2026 at Nuvectis Pharma, up from -$7.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$2.9 million in Q1 2022 to a low of -$7.5 million in Q3 2025.
• The 5-year median for EBT is -$5.9 million (2022), against an average of -$5.5 million.
• Peak annual rise in EBT reached 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
• Nuvectis Pharma's EBT stood at -$6.7 million in 2022, then gained by 1.11% to -$6.6 million in 2023, then grew by 5.65% to -$6.2 million in 2024, then decreased by 17.06% to -$7.3 million in 2025, then increased by 17.28% to -$6.0 million in 2026.
• The last three EBT figures came in at -$6.0 million (Q1 2026), -$7.3 million (Q4 2025), and -$7.5 million (Q3 2025), per Business Quant data.